



Corres. and Mail  
**BOX AF**

**RECEIVED**

JUN 04 2002

TECH CENTER 1600/2900

AF/1617

#24/G

mp  
6/14/02  
N.E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 1469**  
Takeshi SAKAI et al. : **Docket No.00001/F-3511 PT-US-CPA**  
Serial No. 09/269,711 : **Group Art Unit 1617**  
Filed April 5, 1999 : **Examiner S. Wang**  
APOPTOSIS INDUCING AGENT :

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

**AMENDMENT AFTER FINAL**

Assistant Commissioner for Patents,  
Washington, D.C. 20231

**RESPONSE UNDER 37. CFR 1.116**  
**EXPEDITED PROCEDURE**  
**EXAMINING GROUP 1617**

Sir:

Responsive to the Official Action dated March 19, 2002, please amend the above-  
identified application as follows.

**In the Claims:**

Please amend the following claims as shown.

40. (Thrice Amended) A method of inducing apoptosis comprising administering an  
apoptosis inducing agent which comprises glycerolipid as the effective component, to an  
individual.

41. (Amended) The method as set forth in claim 40, wherein said glycerolipid is derived  
from plants, microorganisms or animals.